Venturi Wealth Management LLC Purchases 422 Shares of Illumina, Inc. (NASDAQ:ILMN)

Venturi Wealth Management LLC increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 18.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,650 shares of the life sciences company’s stock after acquiring an additional 422 shares during the period. Venturi Wealth Management LLC’s holdings in Illumina were worth $346,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. UMB Bank n.a. raised its holdings in Illumina by 7.0% in the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after buying an additional 88 shares during the last quarter. Integrated Advisors Network LLC lifted its holdings in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Carson Advisory Inc. grew its stake in shares of Illumina by 3.8% in the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after purchasing an additional 102 shares during the last quarter. Institute for Wealth Management LLC. increased its holdings in Illumina by 4.6% in the second quarter. Institute for Wealth Management LLC. now owns 2,728 shares of the life sciences company’s stock valued at $285,000 after purchasing an additional 119 shares during the period. Finally, Massmutual Trust Co. FSB ADV raised its position in Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $147.62 on Wednesday. The company has a quick ratio of 0.86, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $23.41 billion, a PE ratio of -15.21 and a beta of 1.13. The stock’s 50 day moving average price is $138.50 and its 200-day moving average price is $123.77. Illumina, Inc. has a twelve month low of $92.26 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada increased their price target on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. StockNews.com began coverage on shares of Illumina in a research report on Thursday, August 29th. They issued a “buy” rating on the stock. Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research report on Wednesday, August 28th. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and upped their price target for the company from $120.00 to $154.00 in a research report on Friday, August 16th. Finally, JPMorgan Chase & Co. boosted their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.